Literature DB >> 16299324

Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo.

Jason E Comer1, Ashok K Chopra, Johnny W Peterson, Rolf König.   

Abstract

The causative agent of anthrax, Bacillus anthracis, produces two toxins that contribute in part to its virulence. Lethal toxin is a metalloprotease that cleaves upstream mitogen-activated protein kinase kinases. Edema toxin is a calmodulin-dependent adenylate cyclase. Previous studies demonstrated that the anthrax toxins are important immunomodulators that promote immune evasion of the bacterium by suppressing activation of macrophages and dendritic cells. Here we showed that injection of sublethal doses of either lethal or edema toxin into mice directly inhibited the subsequent activation of T lymphocytes by T-cell receptor-mediated stimulation. Lymphocytes were isolated from toxin-injected mice after 1 or 4 days and stimulated with antibodies against CD3 and CD28. Treatment with either toxin inhibited the proliferation of T cells. Injection of lethal toxin also potently inhibited cytokine secretion by stimulated T cells. The effects of edema toxin on cytokine secretion were more complex and were dependent on the length of time between the injection of edema toxin and the isolation of lymphocytes. Treatment with lethal toxin blocked multiple kinase signaling pathways important for T-cell receptor-mediated activation of T cells. Phosphorylation of the extracellular signal-regulated kinase and the stress-activated kinase p38 was significantly decreased. In addition, phosphorylation of the serine/threonine kinase AKT and of glycogen synthase kinase 3 was inhibited in T cells from lethal toxin-injected mice. Thus, anthrax toxins directly act on T lymphocytes in a mouse model. These findings are important for future anthrax vaccine development and treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16299324      PMCID: PMC1307061          DOI: 10.1128/IAI.73.12.8275-8281.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  56 in total

1.  Designing a polyvalent inhibitor of anthrax toxin.

Authors:  M Mourez; R S Kane; J Mogridge; S Metallo; P Deschatelets; B R Sellman; G M Whitesides; R J Collier
Journal:  Nat Biotechnol       Date:  2001-10       Impact factor: 54.908

2.  Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax.

Authors:  Melissa Drysdale; Sara Heninger; Julie Hutt; Yahua Chen; C Rick Lyons; Theresa M Koehler
Journal:  EMBO J       Date:  2004-12-16       Impact factor: 11.598

3.  Post-thymic selection of peripheral CD4+ T-lymphocytes on class II major histocompatibility antigen-bearing cells.

Authors:  X Shen; R König
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2001-02       Impact factor: 1.770

4.  Internalization and processing of Bacillus anthracis lethal toxin by toxin-sensitive and -resistant cells.

Authors:  Y Singh; S H Leppla; R Bhatnagar; A M Friedlander
Journal:  J Biol Chem       Date:  1989-07-05       Impact factor: 5.157

5.  Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers.

Authors:  B W McBride; A Mogg; J L Telfer; M S Lever; J Miller; P C Turnbull; L Baillie
Journal:  Vaccine       Date:  1998-05       Impact factor: 3.641

6.  Effect of Bacillus anthracis lethal toxin on human peripheral blood mononuclear cells.

Authors:  Serguei G Popov; Rafael Villasmil; Jessica Bernardi; Edith Grene; Jennifer Cardwell; Taissia Popova; Aiguo Wu; Darya Alibek; Charles Bailey; Ken Alibek
Journal:  FEBS Lett       Date:  2002-09-11       Impact factor: 4.124

7.  Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques.

Authors:  B E Ivins; M L Pitt; P F Fellows; J W Farchaus; G E Benner; D M Waag; S F Little; G W Anderson; P H Gibbs; A M Friedlander
Journal:  Vaccine       Date:  1998-07       Impact factor: 3.641

8.  Inhibition of antigen-specific T cell proliferation and cytokine production by protein kinase A type I.

Authors:  Einar Martin Aandahl; Walter J Moretto; Patrick A Haslett; Torkel Vang; Tone Bryn; Kjetil Tasken; Douglas F Nixon
Journal:  J Immunol       Date:  2002-07-15       Impact factor: 5.422

9.  Peptides corresponding to CD4-interacting regions of murine MHC class II molecules modulate immune responses of CD4+ T lymphocytes in vitro and in vivo.

Authors:  X Shen; B Hu; P McPhie; X Wu; A Fox; R N Germain; R König
Journal:  J Immunol       Date:  1996-07-01       Impact factor: 5.422

10.  Anthrax toxin blocks priming of neutrophils by lipopolysaccharide and by muramyl dipeptide.

Authors:  G G Wright; G L Mandell
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

View more
  52 in total

Review 1.  New insights into the biological effects of anthrax toxins: linking cellular to organismal responses.

Authors:  Annabel Guichard; Victor Nizet; Ethan Bier
Journal:  Microbes Infect       Date:  2011-09-08       Impact factor: 2.700

2.  Antibacterial role for natural killer cells in host defense to Bacillus anthracis.

Authors:  Christine M Gonzales; Courtney B Williams; Veronica E Calderon; Matthew B Huante; Scott T Moen; Vsevolod L Popov; Wallace B Baze; Johnny W Peterson; Janice J Endsley
Journal:  Infect Immun       Date:  2011-10-17       Impact factor: 3.441

3.  Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.

Authors:  Ming Yan; Michael H Roehrl; Emre Basar; Julia Y Wang
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

4.  ESAT-6 inhibits production of IFN-gamma by Mycobacterium tuberculosis-responsive human T cells.

Authors:  Xisheng Wang; Peter F Barnes; Karen M Dobos-Elder; James C Townsend; Yoon-tae Chung; Homayoun Shams; Stephen E Weis; Buka Samten
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

5.  Clostridioides difficile Infection Induces an Inferior IgG Response to That Induced by Immunization and Is Associated with a Lack of T Follicular Helper Cell and Memory B Cell Expansion.

Authors:  Souwelimatou Amadou Amani; Tyler Shadid; Jimmy D Ballard; Mark L Lang
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

6.  A dual purpose universal influenza vaccine candidate confers protective immunity against anthrax.

Authors:  Maria T Arévalo; Junwei Li; Diana Diaz-Arévalo; Yanping Chen; Ashley Navarro; Lihong Wu; Yongyong Yan; Mingtao Zeng
Journal:  Immunology       Date:  2016-12-05       Impact factor: 7.397

7.  Suppression of dendritic cell activation by anthrax lethal toxin and edema toxin depends on multiple factors including cell source, stimulus used, and function tested.

Authors:  Ping-Jen Joe Chou; Catherine A Newton; Izabella Perkins; Herman Friedman; Thomas W Klein
Journal:  DNA Cell Biol       Date:  2008-12       Impact factor: 3.311

8.  Amiodarone and bepridil inhibit anthrax toxin entry into host cells.

Authors:  Ana M Sanchez; Diane Thomas; Eugene J Gillespie; Robert Damoiseaux; Joseph Rogers; Jonathan P Saxe; Jing Huang; Marianne Manchester; Kenneth A Bradley
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

9.  Bacillus anthracis edema toxin activates nuclear glycogen synthase kinase 3beta.

Authors:  Jason L Larabee; Kevin DeGiusti; James L Regens; Jimmy D Ballard
Journal:  Infect Immun       Date:  2008-09-02       Impact factor: 3.441

10.  Anthrax infection inhibits the AKT signaling involved in the E-cadherin-mediated adhesion of lung epithelial cells.

Authors:  Taissia Popova; Virginia Espina; Charles Bailey; Lance Liotta; Emanuel Petricoin; Serguei Popov
Journal:  FEMS Immunol Med Microbiol       Date:  2009-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.